BioMerieux Receivables 2017-2023 | BMXMF
BioMerieux receivables from 2017 to 2023. Receivables can be defined as the total amount of collectibles for a company
- BioMerieux receivables for the quarter ending December 31, 2023 were $1.022B, a 22.13% increase year-over-year.
- BioMerieux receivables for 2023 were $1.022B, a 4.65% increase from 2022.
- BioMerieux receivables for 2022 were $0.977B, a 8.47% increase from 2021.
- BioMerieux receivables for 2021 were $0.9B, a 7.91% increase from 2020.
| BioMerieux Annual Receivables (Millions of US $) |
|
|---|---|
| 2023 | $1,022 |
| 2022 | $977 |
| 2021 | $900 |
| 2020 | $834 |
| 2019 | $749 |
| 2018 | $709 |
| 2017 | $663 |
| 2016 | $664 |
| 2015 | $ |
| BioMerieux Quarterly Receivables (Millions of US $) |
|
|---|---|
| 2023-12-31 | $1,022 |
| 2022-12-31 | $977 |
| 2022-06-30 | $879 |
| 2021-12-31 | $900 |
| 2021-06-30 | $837 |
| 2020-12-31 | $834 |
| 2019-12-31 | $749 |
| 2019-06-30 | $700 |
| 2018-12-31 | $709 |
| 2018-06-30 | $700 |
| 2017-12-31 | $663 |
| 2017-06-30 | $628 |
| 2016-12-31 | $664 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.891B | $3.977B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $114.104B | 13.91 |
| Cencora (COR) | United States | $43.338B | 16.56 |
| DiDi Global (DIDIY) | China | $24.254B | 0.00 |
| ICON (ICLR) | Ireland | $24.216B | 21.76 |
| Avantor (AVTR) | United States | $17.207B | 26.09 |
| Natera (NTRA) | United States | $16.059B | 0.00 |
| Revvity (RVTY) | United States | $15.289B | 26.77 |
| Viatris (VTRS) | United States | $13.833B | 4.21 |
| CochLear (CHEOY) | Australia | $13.111B | 0.00 |
| Solventum (SOLV) | United States | $11.699B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.635B | 32.27 |
| Charles River Laboratories (CRL) | United States | $9.848B | 18.61 |
| Sonic Healthcare (SKHHY) | Australia | $8.945B | 0.00 |
| Doximity (DOCS) | United States | $8.138B | 51.56 |
| HealthEquity (HQY) | United States | $7.256B | 39.38 |
| Bausch + Lomb (BLCO) | Canada | $6.689B | 28.79 |
| PACS (PACS) | United States | $5.867B | 0.00 |
| Life Times (LTH) | United States | $4.961B | 41.47 |
| Organon (OGN) | United States | $4.709B | 4.79 |
| Sotera Health (SHC) | United States | $4.475B | 22.57 |
| Surgery Partners (SGRY) | United States | $3.961B | 43.89 |
| GoodRx Holdings (GDRX) | United States | $2.690B | 101.29 |
| Concentras Parent (CON) | United States | $2.655B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.568B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $2.531B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.089B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.961B | 0.00 |
| Premier (PINC) | United States | $1.923B | 8.64 |
| CareDx (CDNA) | United States | $1.630B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.548B | 0.00 |
| Progyny (PGNY) | United States | $1.472B | 25.87 |
| AMN Healthcare Services Inc (AMN) | United States | $1.456B | 7.31 |
| GeneDx Holdings (WGS) | United States | $1.342B | 0.00 |
| Agilon Health (AGL) | United States | $1.321B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.264B | 0.00 | |
| QDM (QDMI) | Hong Kong, SAR China | $1.125B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.042B | 11.34 |
| Embecta (EMBC) | United States | $0.780B | 5.20 |
| InnovAge Holding (INNV) | United States | $0.746B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.529B | 0.00 |
| Sharecare (SHCR) | United States | $0.528B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.455B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.425B | 0.00 |
| Enhabit (EHAB) | United States | $0.376B | 32.52 |
| DocGo (DCGO) | United States | $0.343B | 12.89 |
| Biodesix (BDSX) | United States | $0.245B | 0.00 |
| ModivCare (MODV) | United States | $0.241B | 7.67 |
| Sera Prognostics (SERA) | United States | $0.241B | 0.00 |
| LifeMD (LFMD) | United States | $0.208B | 0.00 |
| Beauty Health (SKIN) | United States | $0.184B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.174B | 0.00 |
| MultiPlan (MPLN) | United States | $0.145B | 0.00 |
| So-Young (SY) | China | $0.125B | 30.25 |
| Nutex Health (NUTX) | United States | $0.111B | 0.00 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.043B | 1.72 |
| SBC Medicals (SBC) | United States | $0.042B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.041B | 0.00 |
| OncoCyte (OCX) | United States | $0.039B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.038B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.034B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.028B | 0.00 |
| Oncology Institute (TOI) | United States | $0.024B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.018B | 0.00 |
| Scienture Holdings (SCNX) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| KindlyMD (KDLY) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |